Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers - Iovance Biotherapeutics

Iovance Biotherapeutics Inc (NASDAQ:IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) in patients with advanced cancers.
Data were presented at the Society for Immunotherapy of Cancer Annual Meeting.
Early-line treatment with single-agent pembrolizumab achieved an overall response rate (ORR) of 33% in patients with advanced melanoma and 17% in head and neck cancer patients.
Cervical cancer patients previously treated with standard-of-care systemic therapy achieved an ORR of 11%-14% with pembrolizumab monotherapy.
In cervical cancer, melanoma, and head & neck cancer cohorts, ORR was 57.1%, 60%, and 38.9%, respectively.
The treatment-emergent adverse event (TEAE) profile across all three cohorts was consistent with the underlying disease and known adverse event (AE) profiles.
Also Read: Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial.
Price Action: IOVA shares are down 8.23% at $19.34 during the market session on the last check Monday.

To add Benzinga News as your preferred source on Google, click here.